Yazar "Seber, Selçuk" için Fakülteler listeleme
-
Approach to Breast Cancer Treatment in Elderly Patients
Seber, Selçuk; Çabuk, Devrim; Başaran, Gül (Ortadogu Reklam Tanitim & Yayincilik, 2020)Old age should be carefully evaluated before the treatment of all kinds of diseases, not only chronologically but also in functional terms. Regardless of the stage of breast cancer, it is known that older patients benefit ... -
Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey
Kilickap, S.; Demirci, U.; Buğdaycı, F.; Tural, D.; Korkmaz, T.; Paydas, S.; Cicin, İrfan; Seber, Selçuk (Elsevier Science Inc, 2019)[No Abstract Available] -
Prognostic values of various hematological variables as markers of systemic inflammation in metastatic lung cancer
Bayir, Duygu; Seber, Selçuk; Yetişyiğit, Tarkan (Wolters Kluwer Medknow Publications, 2020)Background: Chronic state of inflammation is an important factor in advanced cancer which is used by tumor cells for maintaining survival and growth. Hematological parameters such as neutrophil/lymphocyte ratio (NLR), ... -
Retrospective evaluation of totally implantable venous access port devices: Early and late complications
Gürkan, Selami; Seber, Selçuk; Gür, Özcan; Yetişyiğit, Tarkan; Donbaloğlu, Mehmet Okan; Özkaramanlı Gür, Demet (Imprimatur Publications, 2015)Purpose: The role totally implantable vascular devices (TI-VAD) have an important role in providing care to cancer patients who require continuous or frequent venous access route either for their primary or supportive care ... -
Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; in the light of completed trials
Korkmaz, Taner; Seber, Selçuk; Başaran, Gül (Elsevier Science Inc, 2016)Late and recurrent stage ovarian cancer has a high mortality and low response rate to therapy beyond first line treatment. Although first line platinum/taxane based regimens have a satisfactory response rate eventually in ...